<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621551</url>
  </required_header>
  <id_info>
    <org_study_id>2021-1437</org_study_id>
    <nct_id>NCT05621551</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Therapy In Cardiac Surgery</brief_title>
  <official_title>Effects of Perioperative Dapagliflozin on Type 2 Diabetic Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial is to assess the effects of perioperative dapagliflozin on&#xD;
      type 2 diabetic patients undergoing cardiac surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2i) including dapagliflozin are widely used in&#xD;
      the clinical treatment of type 2 diabetes mellitus(T2DM). In recent studies, SGLT2i were&#xD;
      found to not only reduce blood glucose but also protect the heart and kidney, which can&#xD;
      significantly reduce cardiovascular events, delay the progression of renal failure, greatly&#xD;
      improve the quality of life of patients. Patients with T2DM have poorer cardiac surgery&#xD;
      outcomes compared with non-diabetics. Based on the promising pharmacological profile of&#xD;
      dapagliflozin, we hypothesize that perioperative dapagliflozin therapy would improve&#xD;
      postoperative outcomes among patients undergoing cardiac surgery with T2DM. This randomized&#xD;
      controlled trial is to assess the effects of perioperative dapagliflozin on type 2 diabetic&#xD;
      patients undergoing cardiac surgery&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 11, 2022</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hs-Troponin-I</measure>
    <time_frame>within 2 days after surgery</time_frame>
    <description>high sensitive cardiac troponin-I</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>within 5 days after surgery</time_frame>
    <description>N-terminal prohormone of brain natriuretic peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative atrial fibrillation</measure>
    <time_frame>within 5 days after surgery</time_frame>
    <description>In this study, postoperative AF was defined as occurrence of the arrhythmia within the first 5 days after cardiac surgery. AF was considered to be present when an irregular rhythm was detected in the absence of P waves and/or presence an f wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac function</measure>
    <time_frame>within 5 days after surgery</time_frame>
    <description>Echocardiography is used to assess cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>within 5 days after surgery</time_frame>
    <description>Change of creatinine values, need for renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal blood potassium concentration</measure>
    <time_frame>within 5 days after surgery</time_frame>
    <description>blood potassium concentration&lt;3.5mmol/L or &gt;5.5mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative blood glucose level</measure>
    <time_frame>within 5 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-C-reactive protein</measure>
    <time_frame>within 5 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hs-Troponin-I</measure>
    <time_frame>within 5 days after surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Outcome</measure>
    <time_frame>In-hospital time, an average of 2 weeks</time_frame>
    <description>Number of Adverse Events, Serious Adverse Events, Diabetic ketoacidosis, Severe hypoglycemic events, hypovolemia, urogenital tract infection</description>
  </other_outcome>
  <other_outcome>
    <measure>Major adverse cardiac cerebrovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>Exploratory endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Exploratory endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Incision infection</measure>
    <time_frame>In-hospital time, an average of 2 weeks</time_frame>
    <description>Exploratory endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU readmission</measure>
    <time_frame>In-hospital time, an average of 2 weeks</time_frame>
    <description>Exploratory endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU stay</measure>
    <time_frame>Length of ICU stay after surgery，an average of 3 days</time_frame>
    <description>Exploratory endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of in-hospital time</measure>
    <time_frame>In-hospital time, an average of 2 weeks</time_frame>
    <description>Exploratory endpoints</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">178</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care treatment of diabetes patients during perioperative cardiac surgery in our center</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years at screening&#xD;
&#xD;
          2. Scheduled for cardiac surgery&#xD;
&#xD;
          3. Diagnosis of Type 2 Diabetes&#xD;
&#xD;
          4. Provision of signed informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Emergency surgery and non-primary surgery&#xD;
&#xD;
          2. Moderate and severe dehydration; systolic pressure≤90mmHg; unstable haemodynamics&#xD;
&#xD;
          3. History of diabetic ketoacidosis; type 1 diabetes mellitus&#xD;
&#xD;
          4. Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment&#xD;
&#xD;
          5. Known allergy or hypersensitivity to dapagliflozin or other SGLT-2 inhibitors&#xD;
&#xD;
          6. Estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m2 or requiring dialysis;&#xD;
             unstable or rapidly progressing renal disease at the time of randomisation&#xD;
&#xD;
          7. Serious hepatic disease&#xD;
&#xD;
          8. Women who are pregnant, nursing, or who plan to become pregnant while in the trial&#xD;
&#xD;
          9. Currently enrolled in another investigational drug study, or less than 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <phone>+86-010-88396051</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhongchen Li, MD</last_name>
    <email>lizhongchen@fuwai.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Zheng, Poprofessor</last_name>
      <phone>010-88396051</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SGLT2 inhibitors</keyword>
  <keyword>Cardiac Surgery</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

